Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Meta
2/2 12:45
Media Release COPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq: GMAB ) and Pfizer, Inc. (NYSE PFE) today a nnounced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA)...